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Urine protein patterns can serve as diagnostic tools in patients
with IgA nephropathy.
Background. IgA nephropathy (IgAN) is the most common
chronic glomerular disease in adults. End-stage renal disease
(ESRD) develops in about 30% of the patients. Early inter-
vention and consequent therapy may prevent or at least delay
the development of ESRD in these patients. Up to now, the
diagnosis could only be achieved with a renal biopsy.
Methods. The urine of 45 patients with IgAN was collected
and screened for protein/polypeptide patterns with a novel high
throughput method, capillary electrophoreses on-line coupled
to a mass spectrometer (CE-MS). CE-MS allows the fast and
accurate evaluation of up to 2000 polypeptides in one urine
sample. The results in IgAN were compared to findings in 13
patients with membranous nephropathy (MN) and 57 healthy
individuals.
Results. In the patients with IgAN, even when urinary pro-
tein excretion was within the normal range of regular tests,
the polypeptide pattern in urine differed significantly from that
of healthy controls and patients with MN, indicating a specific
“IgAN” pattern of polypeptide excretion. Classification regard-
ing discrimination of IgAN from healthy controls and from MN
had a sensitivity of 100% and 77%, respectively. Specificity was
90% and 100%, respectively. Compared to patterns established
earlier in patients with minimal change disease (MCD), focal
segmental glomerulosclerosis (FSGS), or diabetic nephropathy
(DN), sensitivity and specificity were 100%. Treatment of the
patients was associated with changes of the pattern, possibly
indicating a therapeutic effect.
Conclusion. Proteomic analysis with CE-MS coupling per-
mits fast and accurate identification and differentiation of
polypeptide patterns in the urine of patients with IgAN,
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allowing differentiation from healthy controls and, probably,
other renal diseases.
IgA nephropathy (IgAN) is the most common
glomerulonephritis type in the world [1]. In Europe it
is found in 20%, and in Asia in up to 50%, of all biopsy-
proven cases of glomerulonephritis. Clinical features and
prognosis vary. In general, patients develop painless
micro- and/or macrohematuria and most of them develop
proteinuria, which is usually below the nephrotic range.
Many patients are therefore unaware of the disease and
IgAN is often a chance finding. Less than 5% of patients
with IgAN develop renal failure as the result of a rapidly
progressive glomerulonephritis. However, up to one third
of the patients develop end-stage renal disease (ESRD)
within 20 years after the diagnosis has been made, re-
quiring dialysis or transplantation. Up to now, the diag-
nosis could only be established by renal biopsy, which
usually shows mesangioproliferative glomerulonephritis
with predominant IgA deposits in the mesangium. Dif-
ferential diagnoses include all forms of glomerulonephri-
tides and nephrosclerosis due to hypertension.
Here, we present a promising proteomics-based
technique for the diagnosis of IgAN relying on the es-
tablishment of a total protein/peptide pattern in hu-
man urine with capillary electrophoresis coupled on-line
to an electrospray ionization time-of-flight mass spec-
trometer (CE-ESI-TOF-MS). This technique permits the
rapid identification of the polypeptide pattern in hu-
man urine in a single step [2]. The feasibility of this
approach was tested by the generation of polypeptide
patterns of patients with IgAN and comparison of these
with patterns established in patients with focal segmen-
tal glomerulosclerosis (FSGS), minimal change disease
(MCD), membranous nephropathy (MN) [3], and dia-
betic nephropathy (DN) [4] as well as with those gener-
ated from healthy volunteers.
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METHODS
Patients
Informed consent was obtained from all patients and
healthy controls, after local ethics committee approval.
Urine samples were collected in the morning, after
voiding the first urine of the day, from 45 patients with
biopsy-proven IgAN (median age 41 years, range 19 to
78 years; 12 patients newly diagnosed), 13 patients with
biopsy-proven MN (median age 43 years, range from 21
to 69 years) [3], and 57 healthy volunteers (median age 28
years, range 18 to 56 years). Moreover, urinary patterns of
IgAN were compared to patterns in patients with MCD
(N = 16), FSGS (N = 10), or DN (N = 23) that had been
established earlier [3, 4].
All IgAN patients had a microhematuria (≥5 erythro-
cytes per high power field), none had a macrohematuria
when the samples were taken. The protein excretion rate
was above 1.5 g/day in 14 patients with IgAN and 6 with
MN, between 0.5 and 1.5 g/day in 17 patients with IgAN
and 2 patients with MN and less than 0.5 g/day in 14 pa-
tients with IgAN and 5 with MN. In addition, in 10 of
the patients with IgAN, repeated urine samples were col-
lected after 6 months and 12 months. Clinical data for all
patients with IgAN are summarized in Table 1.
CE-MS
Urinary samples were aliquoted and stored at −80◦C
prior to use. After thawing, the samples were prepared as
previously described [2]. Briefly, 2 mL urine were applied
onto a Pharmacia C2-column (Amersham Biosciences,
Buckinghampshire, UK) to enrich protein and peptides
and to remove urea, salts, and other confounding ma-
terial. Polypeptides were eluted with 2.2 mL 50% ace-
tonitrile in H2O containing 0.5% formic acid (both from
Merck, Darmstadt, Germany). Subsequently the eluate
was separated in two aliquots of 2 mL and 200 lL.
The 200 lL aliquot was lyophilized and resuspended in
50 lL high-performance liquid chromatography (HPLC)-
grade water for a protein determination with the Up-
tima BCA Assay Kit (Interchim, Montlucon Cedex,
France) utilizing a Genova MK3 Life Science Analyzer
(Jenway Ltd., Dunmow, Essex, UK). The 2 mL aliquot
was lyophilized and stored at 4◦C until resuspendation
in HPLC-grade water shortly before use. This resus-
pendation volume was matched to the protein content in
the sample, thus establishing that higher protein content
leads to higher resuspendation volumes. Accordingly, the
protein content in the injected sample is equalized and
this results in amounts of approximately 200 nL of each
sample (1 psi for 20 seconds), which were injected.
The CE (Beckman P/ACE MDQ System) (Beckman-
Coulter, Fullerton, CA, USA) is on-line coupled via a
sheath-flow-interface (Agilent Technologies, Palo Alto,
CA, USA) to an electrospray-ionization time-of-flight
Table 1. Patient characteristics
Serum Antihypertensive
Age creatinine Proteinuria drugs
Gender years lmol/L g/day number
M 37 73 <0.1 1
M 48 88 <0.1 2
M 78 177 <0.1 4
F 36 57 0.1 1
M 29 99 0.1 3
F 33 133 0.1 0
M 47 204 0.1 0
F 39 69 0.2 2
M 44 83 0.2 4
M 19 89 0.3 0
F 29 114 0.3 3
M 47 133 0.4 1
F 34 133 0.4 3
M 41 159 0.4 5
M 59 77 0.5 3
F 25 111 0.5 1
F 58 76 0.6 1
M 46 106 0.9 1
M 68 125 0.9 3
M 63 372 0.9 7
M 31 383 1.0 2
M 57 212 1.2 3
F 31 212 1.2 4
M 34 248 1.2 3
M 34 373 1.2 4
M 65 127 1.2 0
M 51 99 1.3 3
M 26 64 1.4 0
M 72 106 1.4 3
M 43 228 1.4 6
M 46 363 1.4 2
M 32 133 1.6 4
M 59 97 2.0 4
M 46 97 2.6 2
M 35 168 2.6 2
M 20 230 2.8 3
M 59 416 3.0 3
M 38 97 3.1 1
M 37 133 3.6 1
M 58 99 4.0 1
M 58 206 5.6 2
M 20 239 5.8 1
F 34 80 6.2 0
F 38 292 9.8 2
M 47 150 11.0 3
mass spectrometer (ESI-TOF MS) (Perceptive Biosys-
tems, Framingham, MA, USA). The mobile phase and
the sheath liquid consisted of 30% methanol and 0.5%
formic acid in water at pH 2.2. The subsequent CE-MS
run was performed at +30 kV and 0.3 to 1.0 psi positive
pressure for 60 minutes.
Data processing
The vast amount of data generated is not suitable to
be analyzed within a reasonable time with the software
provided by the manufacturer of the MS. Thus, based
on the original software, a special software was gener-
ated to suit the purpose (MosaiquesVisu) [2]. The pro-
gram uses isotopic distribution and conjugated masses for
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determination of the charge of the polypeptides. In a first
electronic analysis, the software identifies all peaks within
each single spectrum. This yields a list of, generally, be-
tween 2000 to 5000 so-called “CE-MS” peaks and these
data are deposited as the raw data “peak list.” In the next
step, the peaks representing identical molecules with dif-
ferent charge states are deconvoluted into a single mass.
The actual mass of the polypeptides plotted against the
migration time gives the “protein-display.” This results
in a theoretic CE-MS spectrum that contains the infor-
mation on mass, migration time, and signal intensity, as a
measure of the relative concentration, for each individual
polypeptide.
In urine, between 300 and 2000 polypeptides could
be detected in an individual sample. To allow compar-
ison and a search for conformity and differences be-
tween the samples obtained from different individuals,
CE migration times were normalized using 79 polypep-
tides (ranging from 0.8 to 10.1 kD), which can frequently
be found in human urine samples as internal standards
[3]. Since the polypeptide content in urine samples is sig-
nificantly different, the signal intensity was normalized
to the total ion current (TIC) as measure for polypep-
tide content. Polypeptides present in different samples
were considered identical, if the mass deviation was less
than ±250 ppm and the CE retention time deviation was
less than ± 5 minutes. This allowed the comparison of
groups of patients according to the diseases studied, and
led to a list of potential markers defined by the differences
in the polypeptide patterns among the groups. Potential
markers specific for IgAN were selected and are shown in
Tables 2 and 3.
Statistical analysis
Statistical analysis to discriminate between the groups
was performed using support vector machines. This tool
has the advantage of discriminating data in high dimen-
sional parameter space. Its fast and stable algorithms
showed good performance in the evaluation of clinical
markers [3–5] and in different areas of biologic analysis,
like DNA arrays [6].
Sequencing of polypeptides and database search
The tandem mass spectrometer analyses (MS-MS)
were performed with a matrix-assisted laser desorp-
tion/ionization time-of-flight (MALDI-TOF-TOF)-MS
(Ultraflex; Bruker Daltonik, Bremen, Germany). The
complete CE run was spotted onto the MALDI target
(one spot every 15 seconds) with the matrix solution
[5 mg/mL a-cyano-4-hydroxy cinnamic acid (CHC) in
50% acetonitrile and 0.5% formic acid] added as sheath
liquid at 1 lL/min. The target was subsequently exam-
ined in MS mode for the polypeptides of interest, based
on the data for molecular weight of the discriminatory




Molecular time Discrimination Control IgAN MN
weight Da minutes factor (N = 57) (N = 45) (N = 13)
879.5 15.6 0.84 93 2 31
2174.9 27.8 0.81 90 9 8
1265.6 23.0 0.77 100 21 31
3405.3 21.6 0.75 93 14 31
1046.5 21.5 0.74 83 2 31
3359.6 26.2 0.72 76 5 0
3582.9 14.2 0.72 79 7 8
1539.7 34.1 0.72 97 30 8
3040.9 25.5 0.72 97 28 15
6171.4 23.0 0.70 86 19 8
2057.3 19.1 −0.71 0 67 85
4712.9 15.8 −0.72 7 74 92
1698.1 18.4 −0.72 24 98 92
1386.9 17.2 −0.75 3 74 92
1851.1 17.8 −0.77 7 81 92
1499.9 17.6 −0.77 10 86 92
1585.0 18.1 −0.77 14 93 85
1943.0 19.5 −0.79 7 86 85
1867.2 18.6 −0.82 3 84 92
2752.4 15.5 −0.83 10 95 85
1811.2 17.9 −0.83 14 98 92
2427.1 16.4 −0.84 10 93 100
Abbreviations are: IgAN, IgA nephropathy; MN, membranous nephropathy.
polypeptides identified in the CE-MS analyses. The
sequence was matched to the available protein databases:
the NCBI-protein library (PubMED, BLAST) for
matches to known proteins.
RESULTS
Urine samples of 45 patients with IgAN were analyzed
and compared to those of 57 healthy volunteers as well as
13 patients with MN. In an individual urine sample from a
healthy individual between 300 and up to 2000 polypep-
tides were detected within the molecular weight range
from 800 up to 70.000 D. The raw data yielded the cor-
responding peak lists and these were deposited in a Mi-
crosoft Access database (Microsoft, Seattle, WA, USA)
for the comparison of individual samples from healthy
volunteers to those of patients with IgAN or MN.
The examination of urine from healthy individuals
yielded a “normal polypeptide pattern,” consisting of 146
polypeptides excreted by more than 50% of healthy indi-
viduals [3]. Thirty-nine of these were present in more than
90%, 73 polypeptides in more than 70%. Differences in
age did not seem to influence the polypeptide patterns
generated. Since the polypeptide content in the samples
differed significantly, the signal intensity was normalized
to the TIC, the total of all signals obtained. This approach
yielded better comparability of the individual samples in
comparison to adjustment of the samples to similar pro-
tein content prior to CE-MS analysis.
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Table 3. Polypeptides discriminating between patients with either
IgA nephropathy (IgAN) or membranous nephropathy (MN)
Frequency%
Molecular Migration time Discrimination IgAN MN
weight Da minutes factor (N = 45) (N = 13)
1556.7 19.6 −0.85 0 85
1252.7 20.5 −0.81 12 92
1484.5 17.5 −0.73 12 85
2483.4 21.6 −0.73 12 85
2553.7 17.7 −0.72 5 77
1455.8 20.7 −0.70 7 77
2229.5 20.2 −0.70 7 77
2014.9 18.1 −0.69 23 92
2464.4 19.8 −0.69 23 92
1845.3 20.1 −0.68 9 77
2135.3 18.1 −0.68 9 77
2599.2 21.0 −0.68 9 77
1465.7 19.4 −0.67 2 69
2475.8 18.8 −0.64 21 85
1365.7 21.2 −0.62 7 69
1381.0 19.8 −0.62 7 69
1539.6 21.8 −0.62 30 92
2421.1 16.1 −0.62 0 62
1793.1 23.0 −0.61 16 77
1545.8 33.5 0.61 84 23
1573.8 27.8 0.61 77 15
3441.6 25.4 0.62 70 8
1195.6 31.4 0.64 79 15
1523.7 33.0 0.65 95 31
3495.5 25.8 0.71 79 8
1239.6 30.6 0.75 91 15
1217.6 30.1 0.78 93 15
3478.6 27.6 0.78 86 8
To obtain the typical polypeptide patterns, the data
from the individual samples were compiled as described
before [7]. A graphic depiction of the typical polypep-
tide patterns is shown in Figure 1. The CE migration
time is plotted against the actual mass and on a third axis
the signal intensity is shown as a color code from black
to white (0 to 25,000 MS counts). Figure 1A shows the
polypeptide pattern of healthy volunteers, compared to
those in Figure 1B, of patients with IgAN, and Figure 1C,
of patients with MN. Each dot shown in these plots rep-
resents an individual polypeptide excreted. Comparison
of all polypeptides deposited within the database led to
the identification of several potential marker molecules
for patients. The 22 polypeptides with the highest dis-
criminatory values are shown in Table 2. These mark-
ers allow discrimination between healthy individuals and
patients with either IgAN or MN. Ten of these markers
belong to the “normal pattern” and are found in more
than 70% of the healthy volunteers, but in less than 32%
of the patients. The other 12 markers are polypeptides
only excreted in patients at frequencies higher than 67%,
while they are rarely detected in the urine of healthy con-
trols (frequencies less than 25%). Thus, the discrimina-
tion factor calculated by comparison of the frequencies
for the relevant molecules shown in Table 2 was always
higher than 0.70. To enable classification of the patients
based on all 22 polypeptides simultaneously, support
vector machines were employed as described previously
[3]. The analysis showed a correct classification of patients
versus healthy volunteers with a sensitivity of 100% and
a specificity of 90% after cross-validation. The markers
shown in Table 2 were discriminatory between patients
and healthy volunteers, independent of the levels of pro-
teinuria. These markers do not allow distinction between
patients with IgAN and MN, and were therefore consid-
ered as markers for renal damage.
The influence of proteinuria on polypeptide patterns
in patients with IgAN was examined as well. No sys-
tematic differences in the frequency of the discriminating
polypeptides with increasing proteinuria or other param-
eters such as gender, age (≥40 years) and serum creati-
nine level (comparison of patients with creatinine <120
lmol/L and ≥120 lmol/L) was observed.
It is notable that patients with IgAN and a protein ex-
cretion within or slightly above the normal range still ex-
creted different polypeptides than healthy controls, thus
allowing a clear distinction.
In an attempt to obtain more insight into the na-
ture of the discriminating markers, sequencing analyses
were performed. Three of the discriminating polypep-
tides have been sequenced. One is a 2752.4 D polypeptide
with a CE migration time of 15.5 minutes, the second is
a 2427.1 D polypeptide with 16.4-minute migration time,
and the third is a 2057.3 D peptide which migrates at 19.1
minutes. All three polypeptides are fragments of serum
albumin. The MS-MS spectrum from the third polypep-
tide is shown in Figure 2.
For the discrimination of patients with IgAN from
other nephropathies the data were scored for differen-
tially excreted polypeptides. Table 3 shows 28 polypep-
tides for the discrimination between IgAN an MN with a
discrimination factor greater than 0.60 for each individual
polypeptide. Nine of the peptides were detected in IgAN
samples with frequencies greater than 69%. These partic-
ular molecules were found in less than 24% of the samples
from patients with MN. The remaining 17 polypeptides
were detected in more than 61% of the samples from pa-
tients with MN, and were found in less than 31% of the
IgAN samples. Application of these marker peptides to
support vector machines yielded a correct classification
IgAN versus MN with a sensitivity of 77% and a speci-
ficity of 100% after cross-validation.
Regarding patients with FSGS studied earlier [3] 16
polypeptides shown in Table 4 discriminate between
IgAN and FSGS. Fourteen polypeptides have a higher
frequency of occurrence in the FSGS samples but two
polypeptides were detected in IgAN samples with higher
frequencies than in FSGS samples. Regarding patients
with MCD [3] and patients with DN [4], 15 polypeptides
were detected that discriminate between IgAN and MCD
and 17 polypeptides which discriminate between patients











































Fig. 1. Protein contour plots of healthy volunteers (A), patients with IgA nephropathy (IgAN) (B) and patients with membranous nephropathy
(MN) (C). The molecular mass per charge is shown on the left and plotted against the migration time in the capillary electrophoresis (CE) (50
minutes). The color-coded scale, indicating the intensity of the signal, is correlated to the concentration of proteins and peptides in the sample.
Fig. 2. Identification of potential biomarker polypeptides with mass spectrometry-mass spectrometry (MS-MS). The polypeptide with the mass of
2057.3 was further examined using matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF-TOF). The MS-MS spectrum with the
annotations of the individual peaks and the sequences of the peptide is shown.
with IgAN and DN (Tables 5 and 6). The application of
support vector machines to these potential biomarkers
resulted in a correct classification of IgAN versus FSGS,
MCD, and DN samples with a sensitivity and a specificity
after cross-validation of 100%, respectively.
Most patients with IgAN receive antihypertensive
medication as the sole means of therapy. In an attempt
to evaluate the influence of antihypertensive therapy on
the polypeptide pattern, the patients with IgAN were
grouped according to the number of antihypertensive
drugs they received. This resulted in three groups, with
0 to 1, 2 to 3, and 4 or more different antihypertensive
drugs per patient.
As shown in Table 7, the number of antihyperten-
sive drugs given seemed to influence the excretion of
several polypeptides. Thirty-two of these are shown in
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Table 4. Polypeptides discriminating between patients with either
IgA nephropathy (IgAN) or focal segmental glomerulosclerosis
(FSGS)
Frequency%
Molecular Migration time Discrimination IgAN FSGS
weight Da minutes factor (N = 45) (N = 10)
1148.7 38.4 −0.91 9 100
1138.7 39.7 −0.79 21 100
1274.6 49.1 −0.78 2 80
1389.7 53.9 −0.70 0 70
1608.3 57 −0.70 0 70
1783.6 61.2 −0.70 0 70
1395.5 50.1 −0.69 11 80
2279.3 43.4 −0.69 21 90
1553 37.1 −0.67 13 80
2183.1 27.5 −0.67 13 80
2414.7 26.9 −0.67 23 90
1224.7 36.6 −0.66 4 70
1839.4 34.5 −0.66 4 70
2687.3 36.9 −0.66 4 70
1517.9 15.8 0.52 62 10
1666.3 25.4 0.52 72 20
Table 5. Polypeptides discriminating between patients with either
IgA nephropathy (IgAN) or minimal change disease (MCD)
Frequency%
Molecular Migration time Discrimination IgAN MCD
weight Da minutes factor (N = 45) (N = 16)
962.6 25.7 −0.71 17 88
2025.9 40.4 −0.7 11 81
2377.7 29 −0.7 11 81
1148.7 38.4 −0.72 9 81
990.5 37.6 −0.73 2 75
1137.7 31.8 −0.73 2 75
3098.6 38.5 −0.73 2 75
1138.7 39.7 −0.79 21 100
1790.9 36.2 −0.82 6 88
1224.7 36.6 −0.84 4 88
1274.6 49 −0.86 2 88
1651.8 55 −1 0 100
1729.4 27.3 0.51 64 13
2502.7 28 0.51 70 19
1517.9 15.8 0.56 62 6
Table 7. With increasing numbers of antihypertensive
drugs, a change of the polypeptide pattern toward “nor-
malization” could be shown. This was not due to differ-
ences in age or proteinuria. Patients with none or one
antihypertensive drug had a lower serum creatinine than
patients with more than one antihypertensive drug (P <
0.05) (Kruskal-Wallis and Mann-Whitney U). However,
regarding the whole group of patients no influence of cre-
atinine on the disciminating markers could be shown.
Ten patients not receiving immunosuppressive therapy
or a change in the number of antihypertensive drugs were
followed for 6 and 12 months to evaluate the stability of
the polypeptide pattern. Changes in the 22 polypeptide
marker molecules defined for the discrimination between
Table 6. Polypeptides discriminating between patients with either
IgA nephropathy (IgAN) or diabetic nephropathy (DN)
Frequency%
Molecular Migration time Discrimination IgAN DN
weight Da minutes factor (N = 45) (N = 23)
2279.3 43.4 −0.66 21 87
1770.6 43 −0.65 9 74
1517.8 36.8 −0.64 23 87
1148.7 38.4 −0.61 9 70
1099.8 29.6 −0.6 36 96
6187.4 37.3 −0.56 9 65
2579.6 41.3 −0.56 40 96
2534.7 33.9 −0.55 23 78
1218.7 12.9 −0.54 11 65
1843.4 35.2 −0.53 30 83
2406.7 30.6 −0.53 30 83
1641.2 42.9 −0.53 4 57
1219.8 56.7 −0,52 0 52
1867.8 27.9 0.51 60 9
1867.8 27.9 0.51 60 9
1517.9 15.8 0.62 62 0
1523.7 43.4 0.7 96 26
patients and healthy controls (Table 2) were below 20%
for 19 markers.
DISCUSSION
IgAN is a chronic mesangioproliferative glomeru-
lonephritis with a highly variable course. Several risk
factors, like male gender, smoking, hypertension, severe
proteinuria, absence of macrohematuria, and histopatho-
logic changes, have been described to be associated with a
poor outcome [1]. Recently, urinary cytokines (involved
in proliferation and repair) have been measured as a po-
tential marker of histopathologic glomerular and tubu-
lointerstitial changes serving as a predictor of long-term
prognosis [8–11]. Thus, in patients with a poor prognosis
a high urinary interleukin-6 (IL-6)/epidermal growth fac-
tor (EGF) ratio [8], elevated levels of urinary monocyte
chemotactic peptide-1 [9], urinary transforming growth
factor-b1 (TGF-b1) [9] and IL-8 have been described
[11]. As the studies of Ranieri et al [8] and Grandaliano
et al [9] showed a good correlation between urinary pro-
tein excretion and gene and protein expression in the
renal tissue, the urine seems to reflect the inflammatory
processes in the kidney itself. However, in the above stud-
ies investigating single cytokines a reliable differentiation
between patients and controls was prevented by the large
overlap in cytokine excretion between the groups [9, 10].
In addition, cytokine excretion could not distinguish be-
tween different disease entities [8, 10, 12], which is not
unexpected since the inflammatory response is often me-
diated by similar effector molecules.
The method used in our investigation, in contrast, al-
lows the identification of a polypeptide pattern of up to
600 proteins. Compared to genomic approaches, which
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Table 7. Influence of the number of antihypertensive drugs on the




Molecular weight Da 0 0 and 1 2 and 3 ≥4
1195.6 69 87 81 73
1261.5 66 87 69 64
1422.6 48 87 69 45
2566.7 3 87 75 64
1157.5 62 80 69 36
2189.5 38 80 56 18
4712.9 7 80 75 64
1143.6 48 73 56 55
1518.1 48 73 69 45
1878.5 7 67 62 36
2147.0 14 67 69 36
2151.0 0 67 38 18
2196.8 69 67 75 36
2314.1 34 67 19 27
2393.9 59 67 38 36
1307.7 10 60 12 27
1666.8 0 60 12 18
1955.0 10 60 56 45
1981.3 24 60 56 45
2405.6 0 60 75 36
8838.5 38 60 50 9
1576.5 0 53 25 18
2302.4 0 53 62 18
2318.3 7 53 44 36
3325.6 0 53 25 18
1531.7 3 53 25 18
1737.9 93 67 94 100
1438.5 97 40 62 82
1255.6 86 73 69 82
3841.4 86 40 38 55
1268.3 59 7 25 45
1529.6 41 27 12 64
Patients number 16 20 9
Gender M:F 11:5 16:4 8:1
Age years 37 46 43
Serum creatinine lmol/L Mediana Median Median
102 142 177
Proteinuria g/day 0.8 1.3 1.2
aP < 0.05 compared to the other groups.
lead to a pattern of activated or deactivated genes, pro-
teomic analysis has the advantage of visualizing co- and
posttranslational modifications of proteins, possibly of
relevance for biologic function. Alternative approaches
of measuring polypeptides, like the classic method of
comparing data from two-dimensional electrophoresis,
subsequent isolation of the proteins from the gel and anal-
ysis via MS [13] are too time-consuming for routine use.
Moreover, smaller proteins are difficult or even impossi-
ble to visualize. Another method, the surface-enhanced
laser desorption and ionization (SELDI), recently pre-
sented by several groups [14–16], is fast but appears to
have several drawbacks, such as the low resolution and
the loss of most proteins and peptides due to the matri-
ces selecting particular polypeptides [7]. In contrast, the
on-line combination of CE and MS represents a tool for
visualizing a large number of native polypeptides, result-
ing in proteomic patterns discriminating between healthy
volunteers and different patient groups. Moreover, the
“disease-related” peptides allowed the distinction of pa-
tients with IgAN from those with MN and other groups
like patients with MCD, FSGS, or DN. Even patients with
a protein excretion within the normal range (i.e., patients
with IgAN in complete remission) could be classified
correctly according to their protein pattern. Therefore
a discrimination sensitivity of 100% could be achieved
for patients versus normal controls and a specificity of
100% for the differentiation between IgAN and MN and
MCD, FSGS, and DN [3, 4]. Thus, proteomic analysis us-
ing CE-MS coupling appears to be a promising diagnos-
tic tool for early identification of glomerulonephritis and
may be used for differential diagnosis before biopsy in the
future.
In general, no significant degradation of the polypep-
tides in urine could be observed for a period of up to
6 hours at room temperature or after storage at −20◦C
for several months. In fact, even urine samples that were
stored for 5 years at −20◦C still gave good results.
The mass deviation allowed for a given polypeptide was
set higher than necessary since the instrument used is ca-
pable analyze ions with a mass deviation of <50 ppm.
However, this is only the case if significant amounts of
polypeptide are present in the sample. Low signal inten-
sity also results in lower resolution and mass accuracy,
hence mass deviation of ± 250 ppm was allowed. Pre-
liminary data indicate that the use of newer generation
TOF instruments should enable to significantly reduce
the mass deviation to approximately ± 25 ppm.
In contrast, no significant improvement is expected
with respect to migration time deviation. Increased ion
content in the sample (most likely due to polypeptide con-
tent) results in an extension of migration times. Since, in
addition, interaction between the different ions in these
highly complex samples cannot be accounted for, a fairly
high migration time deviation has to be allowed. It should
be pointed out that, when using a set of polypeptide stan-
dards, mass deviation in consecutive CE-MS ran was be-
low 50 ppm and migration time deviation was below 2
minutes.
The analysis of urine from patients with IgAN using
CE-MS yielded a number of discriminatory polypeptides,
22 of which are shown in Table 2 and form the diagnostic
pattern for IgAN. Half of the discriminatory polypeptides
were detected in the majority of the patient samples, while
11 were detected mainly in the normal control samples.
This is an unexpected result, since one would expect to
find polypeptides secreted by healthy volunteers also in
the urine of patients. One possible interpretation may be
that the processing and/or the secretion of polypeptides
is disturbed in patients due to subclinical tubular damage
or that peptides missing in patients may be involved in
the pathogenesis of the disease.
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It cannot be entirely excluded that cells in the urine
(for example, erythrocytes in IgAN) may influence
the diagnostic pattern, as all patients with IgAN had
microhematuria. However, microhematuria was also
found in patients with other forms of glomerulonephri-
tis. In addition, a large number of polypeptides which are
commonly present in samples from healthy individuals
were also found in samples from IgAN patients. There-
fore, it appears that at least most polypeptides are unaf-
fected by cells in urine. On the other hand, there is no
evidence that the polypeptides detected are a result of
cells in urine. Similar considerations are also applicable
to other potential postrenal modifications. It cannot be
excluded that such modification might occur. In fact, it is
likely that modifications like proteolysis might occur to a
limited extent. However, there are no data indicating that
postrenal processing strongly influences the polypeptides
which are utilized as biomarkers for renal diseases.
Sequencing of three of the discriminatory molecules,
only present in the majority of the patient samples, led to
the identification of three different fragments of serum
albumin. One may speculate that this indicates either a
problem in reabsorption of albumin in the patients and/or
may relate to an increase in protease activity due to in-
flammation processes ongoing in the kidneys of patients.
In an effort to examine whether the influences of dif-
ferent therapies would be reflected in pattern changes,
the data were grouped according to the number of an-
tihypertensive drugs given to the patients. As shown in
Table 7, increasing numbers of antihypertensive drugs re-
sult in a trend toward “normalization” of the excretion of
several polypeptides. Therefore, urinary protein patterns
might also be useful for monitoring the therapeutic effi-
cacy, in addition to the differential diagnosis of chronic
nephropathies.
CONCLUSION
Our data indicate that proteomic analysis of urine with
CE-MS coupling is a fast, reproducible, and sensitive ap-
proach for diagnosing IgAN and may help to avoid biop-
sies in the majority of the patients.
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